|
Friday, May 30, 2025, Chicago, Illinois, 6:30 PM – 8:30 PM Central Time (7:30 PM – 9:30 PM Eastern Time)
Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung CancerA CME Symposium Held in Conjunction with the 2025 ASCO® Annual Meeting
Location
Hilton Chicago 720 South Michigan Avenue Chicago, Illinois Phone: (312) 922-4400 Program Schedule — Central Time 6:00 PM – 6:30 PM — Registration and Dinner 6:30 PM – 8:30 PM — Educational Meeting Meeting Room Continental Room A&B (Lobby Level) Faculty
Nicolas Girard, MD, PhD Head of Medical Oncology, Institut Curie Full Professor UVSQ, Paris-Saclay University Paris, France Jonathan Goldman, MD Professor of Medicine UCLA Hematology and Oncology Director of Clinical Trials in Thoracic Oncology Associate Director of Drug Development UCLA Health Santa Monica, California Pasi A Jänne, MD, PhD, FASCO Senior Vice President for Translational Medicine Lowe Center for Thoracic Oncology Professor of Medicine Harvard Medical School David M Livingston, MD, Chair Director, Robert and Renée Belfer Center for Applied Cancer Science Director, Chen-Huang Center for EGFR-Mutant Lung Cancers Dana-Farber Cancer Institute Boston, Massachusetts Suresh S Ramalingam, MD Executive Director, Winship Cancer Institute Roberto C Goizueta Chair for Cancer Research Emory University School of Medicine Atlanta, Georgia Joshua K Sabari, MD Attending Physician Thoracic Medical Oncology Assistant Professor of Medicine NYU Langone Health Perlmutter Cancer Center New York, New York Moderator Helena Yu, MD Medical Oncologist Associate Attending Memorial Sloan Kettering Cancer Center New York, New York This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Johnson & Johnson, and Taiho Oncology Inc.
Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner 6:30 PM – 8:30 PM — Educational Meeting Topics to Be Discussed
Target Audience
CME Credit Form FACULTY — The following faculty reported relevant financial relationships with ineligible entities: Prof Girard — Advisory Committees: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Baxter International Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, Janssen Biotech Inc, LEO Pharma, Lilly, MSD, Pfizer Inc, Pierre Fabre, Sanofi, Suven Pharma, Takeda Pharmaceutical Company Limited; Contracted Research (Through Institution): AstraZeneca Pharmaceuticals LP, MSD; Data and Safety Monitoring Boards/Committees: Roche Laboratories Inc; Speakers Bureaus: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, MSD, Sanofi; Nonrelevant Financial Relationships: Clinical Care Options, PeerVoice. Dr Goldman — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pfizer Inc, Summit Therapeutics; Contracted Research: AbbVie Inc, Agenus Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, RayzeBio Inc, Summit Therapeutics, Tango Therapeutics. Dr Jänne — Advisory Committees: AbbVie Inc, Accutar Biotechnology Inc, Allorion Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Inc, Dizal Pharma, Duality Biologics, Eisai Inc, Frontier Medicines, Genentech, a member of the Roche Group, GSK, Hongyun Biotechnology, Lilly, Merus, Mirati Therapeutics Inc, Monte Rosa Therapeutics, Myris Therapeutics, Novartis, Nuvalent, Pfizer Inc, Roivant, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, TOLREMO, Transcenta, Voronoi; Contracted Research (All to Institution): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Lilly, Puma Biotechnology Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc; Royalties: Postmarketing royalties from Dana-Farber Cancer Institute-owned intellectual property on EGFR mutations licensed to Labcorp; Stock Options — Private Company: Frontier Medicines. Dr Ramalingam — Contracted Research (Research Support to Institution): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc, Johnson & Johnson Pharmaceuticals (no honorarium received). Dr Sabari — Advisory Committees and Consulting Agreements (Advisory Boards/Consultant, Personal Fees): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research (Institutional): Bristol Myers Squibb, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc. MODERATOR — Dr Yu — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Bristol Myers Squibb, Cullinan Therapeutics, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Pfizer Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research (To Institution): AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Cullinan Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc, Kumquat Biosciences, SystImmune Inc, Taiho Oncology Inc; Data and Safety Monitoring Boards/Committees: Janssen Biotech Inc, Mythic Therapeutics. RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Johnson & Johnson, and Taiho Oncology Inc. Hilton Chicago
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited. NOTICE: Registration for this event is independent of registration for the 2025 ASCO® Annual Meeting. IN-PERSON Registration for clinicians in practice/healthcare professionals
I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer. IN-PERSON Registrationfor clinicians » IN-PERSON Registration for other/industry professionals*
Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis. IN-PERSON Registrationfor nonclinicians »
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals
Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions. REGISTRATION FOR WEBCAST »Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at
Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings. Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event. Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation. |